Biomarkers of response to cabozantinib in patients with neuroendocrine tumors
Researcher: Jennifer Chan, M.D., M.P.H. Location: Dana-Farber Cancer Institute State: Massachusetts Year: 2018 Status: Active Award: Pilot Project
Leave it blank
This one-year Pilot Project will evaluate data and patient samples from a phase II clinical trial of cabozantinib, a targeted therapy that showed promise in treating NETs. Cabozantinib has been shown to induce cancer cell death in other types of cancers. In this study, Chan and colleagues will analyze samples from their clinical trial to look for biomarkers that could predict response to cabozantinib. Their findings will be applied to a future investigation in a phase III clinical trial of cabozantinib in NET planned by Chan and colleagues.
NET Research Foundation
321 Columbus Avenue, Suite 5R
Boston MA 02116